Goldman Sachs Starts CG Oncology (CGON) at Neutral, 'Meaningful opportunity for potentially best-in-category bladder cancer agent'
Tweet Send to a Friend
Goldman Sachs analyst Corinne Johnson initiates coverage on CG Oncology (NASDAQ: CGON) with a Neutral rating and a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
